(Adnkronos) - “Il nostro studio Amplify sulla leucemia linfatica cronica è stato individuato come uno dei migliori presentati quest'anno al Congresso Ash della Società Americana di Ematologia e questo ci dà davvero molta soddisfazione. Nello studio abbiamo portato una terapia fissa orale con due meccanismi d'azione che ha dato risultati importanti e anche una buona tollerabilità. L’intento è rendere possibile a tutti i pazienti di portare avanti questo trattamento e di avere questi successi terapeutici”. Così Paola Morosini, medical head oncology di Astrazeneca, in occasione della conferenza stampa dedicata alla presentazione dei risultati dello studio clinico di fase III Amplify, sull’impiego di acalabrutinib e venetoclax come primo regime completamente orale a durata fissa di un inibitore della tirosin-chinasi di Bruton di seconda generazione nel trattamento di prima linea della leucemia linfatica cronica, e dello studio Echo su acalabrutinib in combinazione con chemio-immunoterapia nel trattamento di prima linea di pazienti over 65 con linfoma mantellare.
Category
🗞
NewsTranscript
00:00We are very excited and proud to be back at ASH, the American Society of Hematology.
00:12Our Amplify study in chronic lymphedema has been recognized as one of the best studies presented this year.
00:21It is a study in chronic lymphedema where we carried out an oral therapy with two mechanisms of action,
00:32which really gave important results and also good tolerability,
00:36thus making it possible for all patients to carry out this treatment and to have these therapeutic successes.
00:44However, we are not stopping here.
00:46We have also had data in chronic lymphedema, a rare and aggressive disease.
00:52For patients over 65 years of age and for this pathology, there have been no innovations in recent years.
01:00Instead, we arrive with the association with our molecule, with acalabrutinib, and therefore we are really happy.
01:07However, let's say that it is not enough.
01:09We have entered this area, which is super-specialistic, so really very complex.
01:14In this area, we want to continue to bring innovation and research, and we are doing this.
01:20With more than 100 studies in oncology in Italy, almost 10% are in hematology and, above all, they continue to grow over the years.
01:27So we are not stopping here.
01:29We have new molecules and, above all, we want to go to new pathologies,
01:33where we want to bring our contribution to take steps forward.
01:37And we hope to have other successes in this field.